ArticleFrontiers in psychiatry2026
Feasibility of home-based accelerated intermittent theta-burst stimulation (aiTBS) for depression: a case series.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Transcranial magnetic stimulation (TMS) is an established treatment option for major depressive disorder (MDD) but is currently limited to clinical settings such as hospitals or doctors' offices. Technical and logistical challenges have so far prevented its application in patients' homes. Methods: In this pilot study, five outpatients with MDD (aged 29-65 years), living up to 120 km from a tertiary care hospital (Regensburg, Germany), received home-based TMS treatment using an accelerated intermittent theta burst stimulation protocol (aiTBS; 5 sessions per day, 1800 pulses per session). Treatment was delivered using a conventional DuoMAG XT-100 device (Deymed Diagnostics, Hronov, Czech Republic). Feasibility was evaluated through assessment of logistical challenges, device handling, safety, treatment tolerability and patient satisfaction. Depressive symptoms were measured before and after treatment using the 21-item Hamilton Depression Rating Scale (HAMD-21) and the Major Depression Inventory (MDI). Results: Home-based TMS treatment was feasible with no serious adverse events reported. A reduction in depressive symptom scores was observed. Major logistical challenges included device transport, space requirements and the need for trained personnel on site. Conclusion: Our pilot data demonstrate the feasibility of home-based TMS using a conventional clinical device, while highlighting substantial technical and logistical limitations. These limitations underscore the urgent need for the development of lightweight, portable and patient-friendly TMS devices to facilitate the delivery of neurostimulation therapies beyond clinical settings. Further studies with larger samples are warranted, using randomized controlled designs comparing home-based and clinic-based TMS to evaluate not only feasibility, but also efficacy under standardized conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.